Factor VIII polymer conjugates
View Patent ↗The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
1. A unit dose of a pharmaceutical composition effective to maintain a FVIII molecule at a level of at least 1% in a patient suffering from a bleeding disorder, comprising (i) a conjugate comprising a native Factor VIII modified with a water soluble polymer bound thereto, said water soluble polymer attached to the modified Factor VIII via an oxidized carbohydrate moiety, said modified Factor VIII retaining at least 50% of native FVIII activity, and (ii) a pharmaceutically acceptable excipient.
2. The unit dose of claim 1 , wherein said composition is substantially free from albumin.
3. The unit dose of claim 1 , wherein said water soluble polymer is attached to said oxidized carbohydrate moiety via a linker.
4. The unit dose of claim 3 , wherein said linker is 4-[4-N-malcimidophenyl]butyric acid hydrazide (MBPH).
5. The composition of claim 3 , wherein the linker is releasable or hydrolysable.
6. The composition of claim 1 , wherein said oxidized carbohydrate moiety is located in a native Factor VIII B domain.
7. The unit dose of claim 1 , wherein the pharmaceutical composition is housed in a vessel.
8. The unit dose of claim 1 , wherein the pharmaceutical composition is housed in a syringe.
9. The unit dose of claim 1 , in a form suited for injection.
10. The unit dose of claim 9 , wherein the composition is in a powder form for reconstitution with a diluent prior to injection.
11. The unit dose of claim 10 , reconstituted with a diluent.
12. The unit dose of claim 1 , wherein the composition comprises a plurality of conjugates, each having at least one water soluble polymer bound to a native Factor VIII, said water soluble polymer attached to the modified Factor VIII via one or more oxidized carbohydrate moieties, said modified Factor VIII retaining at least 50% of native FVIII activity, and (ii) a pharmaceutically acceptable excipient.
13. The unit dose of claim 1 , further comprising an unconjugated Factor VIII moiety.
14. The unit dose of claim 1 , wherein each water-soluble polymer in the composition has a nominal average molecular weight in a range of from about greater than 5,000 Daltons to about 150,000 Daltons.
15. The unit dose of claim 1 , wherein each water-soluble polymer in the composition is selected from the group consisting of polyethylene glycol (PEG), polysialic acid (PSA) and dextran.
16. The unit dose of claim 15 , wherein each conjugate in the composition comprises the same water-soluble polymer.
17. The unit dose of claim 16 , wherein the water-soluble polymer has a nominal average molecular weight in the range of from about 2,000 Daltons to about 150,000 Daltons.
18. The unit dose of claim 16 , wherein the water-soluble polymer has a nominal average molecular weight in the range of from about 5,000 Daltons to about 50,000 Daltons.
19. The unit dose of claim 16 , wherein each water-soluble polymer is linear.
20. The unit dose of claim 16 , wherein each water-soluble polymer is branched.
21. The unit dose of claim 16 , wherein the Factor VIII is recombinant Factor VIII.
22. The unit dose of claim 16 , wherein the Factor VIII is plasmatic Factor VIII.
23. A kit comprising a unit dose of a pharmaceutical composition according to claim 1 comprising (i) a conjugate comprising a native Factor VIII modified with a water soluble polymer bound thereto, said water soluble polymer attached to the modified Factor VIII via an oxidized carbohydrate moiety, said modified Factor VIII retaining at least 50% of native FVIII activity, and (ii) a pharmaceutically acceptable excipient; packaged in a container with a label that describes use of the pharmaceutical composition.
24. A kit according to claim 23 , wherein the pharmaceutical composition is packaged in a unit dose form.
25. A kit comprising a unit dose of a pharmaceutical composition according to claim 1 , said kit comprising a first container comprising a conjugate comprising a native Factor VIII modified with a water soluble polymer bound thereto, said water soluble polymer attached to the modified Factor VIII via an oxidized carbohydrate moiety, said modified Factor VIII retaining at least 50% of native FVIII activity, and a second container comprising a physiologically acceptable reconstitution solution for said conjugate in the first container, wherein said kit is packaged with a label that describes use of the pharmaceutical composition.
26. A kit according to claim 25 , wherein the pharmaceutical composition is packaged in a unit dose form.